Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Teirstein

Interventional Cardiology La Jolla, CA Medical Doctor

NPI 1548210768 CMS profile 24158

9898 Genesee Ave, La Jolla, CA 92037

Open in the dashboard

General payments

$518,156

852 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$400,001

1 holding reported · through program year 2025

Research they led as principal investigator

$1,368,255 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Paul Teirstein of La Jolla, CA is reported in the CMS Open Payments database as having received $518,156 across 852 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,368,255 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $400,001 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122,293 148
2024 General $117,548 156
2023 General $83,953 141
2022 General $65,280 152
2021 General $25,216 86
2020 General $36,051 66
2019 General $67,815 103
2024 Ownership $400,001 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Teirstein
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Paul Teirstein were reported at $122,293. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Paul Teirstein Interventional Cardiology median Middle half National median
2019 $67,815 $1,097 $329–$3,048 $163
2020 $36,051 $473 $161–$1,480 $114
2021 $25,216 $677 $233–$1,827 $132
2022 $65,280 $978 $333–$2,724 $149
2023 $83,953 $1,136 $382–$2,986 $160
2024 $117,548 $1,181 $395–$3,326 $164
2025 $122,293 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $157,591 148 payments
  2. Shockwave Medical, Inc $136,916 118 payments
  3. Medtronic Vascular, Inc. $64,378 58 payments
  4. Boston Scientific Corporation $61,429 112 payments
  5. Abiomed $31,551 50 payments
  6. Edwards Lifesciences Corporation $24,489 46 payments
  7. Biotronik Inc. $16,658 21 payments
  8. SpectraWAVE, Inc $4,287 9 payments
  9. HeartFlow, Inc. $4,190 7 payments
  10. Abbott Laboratories $3,345 37 payments
  11. Other $13,322 246 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $212,018 57 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $106,700 24 payments
  3. Consulting Fee $48,825 26 payments
  4. Food and Beverage $46,292 662 payments
  5. Honoraria $26,200 10 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $26,000 2 payments
  7. Travel and Lodging $23,607 62 payments
  8. Grant $18,000 2 payments
  9. Royalty or License $10,161 1 payment
  10. Entertainment $286 3 payments
  11. Other $67 3 payments
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $128,705 93 payments
  2. FFRANGIO $88,027 22 payments
  3. Impella $31,014 40 payments
  4. Resolute Stents $30,202 28 payments
  5. General - Vascular Access $28,560 14 payments
  6. RESOLUTE ONYX $15,230 19 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $8,035 24 payments
  8. CoreValve Evolut $7,430 13 payments
  9. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $5,452 24 payments
  10. Resolute Stents $4,848 6 payments
  11. Other $50,836 561 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$348,668

Medicare's payments for the services billed

Medicare patients

438

Average age 77

Services billed

2,310

136 women, 302 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 50%
Heart failure 49%
Diabetes 43%
Atrial fibrillation 42%
Chronic kidney disease 41%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
$75 — —
LEQVIO
$28 — —
CREON
$17 — —
ENTRESTO
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

852 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record